Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.18%
#2 0G 0G +27.29%
#3 Pons Pons +26.97%
#4 SAFEcoin SAFEcoin +26.87%
#5 Zora Zora +25.96%
#6 Seeker Seeker +23.15%
#7 VVS Finance VVS Finance +21.62%
#8 Full Moon Full Moon +17.50%
#9 ADO Protocol ADO Protocol +16.58%
#10 Apertum Apertum +15.82%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Impact Therap-b Impact Therap-b

Impact Therap-b

7630
Kedudukan dalam Saham #13207
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and... IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Harga Saham
$1.85
Modal Pasaran
$510.85M
Perubahan (1 hari)
-7.37%
Perubahan (1 tahun)
-
Negara
CN
Perdagangan Impact Therap-b (7630)

Kategori

Healthcare
Nisbah P/E bagi Impact Therap-b (7630)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Impact Therap-b, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Impact Therap-b dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 39.54 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.10 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 70.28 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 107.81 -
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.